Account
Inquiry
Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This peptide is primarily developed for research into type 2 diabetes treatment and weight management studies. It exhibits a higher affinity for GIP receptors compared to GLP-1 receptors, contributing to enhanced glucose control and weight reduction effects in preclinical models.
In clinical research, Tirzepatide has demonstrated significant efficacy in improving glycemic control and promoting weight loss. Studies such as SURMOUNT-1 have shown average weight reductions of 15% to 20.9% over 72 weeks, depending on dosage. It is designed as a once-weekly administration peptide, combining the benefits of GIP and GLP-1 agonism into a single molecule for streamlined research applications.
The peptide features a molecular structure similar to semaglutide, with a PEG-modified lysine side chain that enhances water solubility. This modification supports better stability and efficacy in research settings. Tirzepatide is supplied as a white powder, packaged in vials to ensure purity and ease of use for laboratory purposes.
This product is intended for research use only and is not for human consumption. Proper storage conditions include keeping the peptide in a cool, dry, and dark environment to maintain integrity. Avoid repeated freezing and thawing, light exposure, and prolonged storage in solution to preserve its research quality.
